Shots:
- The US FDA has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED), with immediate launch planned across the US. Also, SC elegrobart BLA filing for TED on track for Q1’27
- Approval was granted under FDA Priority Review & supported by the P-III THRIVE (active TED) & THRIVE-2 (chronic TED) trials, which met their respective 1 & 2EPs, showing improvements at Wk. 15 across all of the key signs & symptoms of TED
- Lumvoa demonstrated rapid clinical benefit, reducing proptosis as early as Wk. 3 & significantly improving both diplopia response & complete resolution in active and chronic TED
Ref: Businesswire | Image: Viridian Therapeutics | Press Release
Related News: Viridian Therapeutics Releases the Long-Term Durability Data Evaluating Veligrotug in P-III (THRIVE) Study in Active TED
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
